Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: A potential predictor of short-term outcome?

Neuropsychobiology

Volumn 38, Issue 1, 1998, Pages 19-24

  Agelink, M W ^a   Malessa, R ^b   Kamcili, E ^a   Zeit, T ^a   Lemmer, W ^a   Bertling, R ^a   Klieser, E ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

30:15 ratio; Autonomic nervous system; Clozapine; Deep breathing; Haloperidol; Handgrip; Heart rate variability; Schellong; Schizophrenia; Valsalva

Indexed keywords

BIOLOGICAL MARKER; CATECHOLAMINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HAND GRIP; HEART RATE VARIABILITY; HUMAN; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CHI-SQUARE DISTRIBUTION; CLOZAPINE; FEMALE; HALOPERIDOL; HAND STRENGTH; HEART RATE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SCHIZOPHRENIA; TREATMENT OUTCOME; VALSALVA MANEUVER;

EID: 0031851646     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026512     Document Type: Article

References (28)

1. Casanova MF, Stevens JR, Kleinman JE: The neuropathology of schizophrenia. Old and new findings; in Lindenmayer JP, Kay SR (eds): New Biological Vistas on Schizophrenia. Clinical and Experimental Psychiatry Monographs No 6. New York, Brunner Mazel, 1992, pp 82-109.
2. Scholl HP, Kasper S: Die Bedeutung neurophysiologischer Methoden bei der Vorhersage des Therapieerfolges auf Neuroleptika bei schizophrenen Patienten; in Möller HJ (cd): Therapieresistenz unter Neuroleptikabehandlung. Wien, Springer, 1993, pp 49-67.
3. Volz HP, Mackert A, Diefenbacher A, Friedrich A, Gaebel W, Müller H, Stock G, Möller HJ: Orthostatic challenge during neuroleptic test dose: A possible predictor of short-term outcome. Neuropsychobiology 1994;30:94-100.
4. Gaebel W, Pietzcker A, Ulrich G, Schley J, Müller-Oerlinghausen B: Möglichkeiten der Voraussage des Erfolges einer Akutbehandlung mit Perazin anhand der Reaktion auf eine Perazin-Testdosis; in Heimchen H, Hippius H, Tölle R (eds): Therapie mit Neuroleptika - Perazin. Stuttgart, Thieme, 1988, pp 159-172.
5. Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
6. Ewing DJ, Clarke BF: Autonomic neuropathy: Its diagnosis and prognosis. Clin Endocrinol Metab 1986;15:855-889.
7. Ewing DJ, Clarke BF: Diagnosis and management of diabetic autonomic neuropathy. Br Med J 1982;285:916-918.
8. Malessa R, Ohrmann P, Agelink MW, Brockmeyer NH, Diener HC: HIV-1 assoziierte autonome Dysfunktion (HIVAD). Nervenarzt 1996;67:147-154.
9. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49:345-353.
10. Breier A: Clozapine and noradrenergic function: Support for a novel hypothesis for superior efficacy. J Clin Psychiatry 1994;55(suppl B): 122-125.
11. Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, Davis KL: Treatment with clozapine and its effects on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 1993;46:151-163.
12. Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ: Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res 1993;46:139-149.
13. Ackenheil M: Clozapine: Pharmacokinetic investigation and biochemical effects. Psychopharmacology (Berl) 1989;99:S32-S37.
14. Eckberg DL: Parasympathetic cardiovascular control in human disease: A critical review of methods and results. Am J Physiol 1980;239: H851-H953.
15. Hornykiewicz O: Brain catecholamines in schizophrenia. A good case for noradrenaline. Nature 1982;299:484-486.
16. Müller-Spahn F, Hock C, Kurtz G: Neurochemical and neuroendocrine measures and prediction of outcome to neuroleptic therapy: in Gaebel W, Awad AG (eds): Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Concepts and Methods. Wien, Springer, 1994, pp 111-122.
17. Kammen van DP, Gelernter J: Biochemical instability in schizophrenia. The norepinephrine system; in Meltzer HY (ed): Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987, pp 745-751.
18. Bowers MB, Swigar ME, Jatlow PI, Goicoechea N: Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 1984;45:248-251.
19. Bowers MB, Swigar ME, Huffman FJ, Goicoechea N: Characteristics of patients with the highest plasma catecholamine metabolite levels. Am J Psychiatry 1988;145:246-248.
20. Chang WH, Chen TY, Lin SK, Lung FW, Lin WL, Hu WH, Yeh EK: Plasma catecholamines metabolites in schizophrenics: Evidence for the two subtype concept. Biol Psychiatry 1990;27: 510-518.
21. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnola M, Paul SM: Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: Correlation with psychosis and response treatment. Arch Gen Psychiatry 1986;43:669-676.
22. Mazure CM, Nelson JC, Jatlow PI, Bowers MB: Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 1991;30:475-482.
23. Kahn RS, Davidson M, Knott P, Amin F, DuMont K, Rizzuto P, Apter S, Davis KL: Plasma homovanillic acid concentrations decrease in responders, but not in non-responders to neuroleptic treatment. Schizophr Res 1991; 4:347.
24. Lambert G, Eisenhofer G, Cox H, Home M, Kaliff V, Kelly M, Jennings G, Esker M: Direct determination of homovanillic acid release from the human brain: An indicator of central dopaminergic activity. Life Sci 1991;49:1061-1072.
25. Amin F, Davidson M, Davis KL: Homovanillic acid measurement in clinical research: A review of methodology. Schizophr Bull 1992; 18:123-148.
26. Ko NG, Jimerson DC, Wyatt RJ, Bigelow LB: Plasma 3-methoxy-4 hydroxyphenylglycol changes associated with clinical state and schizophrenia subtype. Arch Gen Psychiatry 1988;45:842-846.
27. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Scharpe J: A prospective study of clozapine in treatment resistant schizophrenic patients. I. Preliminary report. Psychopharmacology 1989;99:S68-S72.
28. Zahn TP, Frith CD, Steinhauer SR: Autonomic functioning in schizophrenia: Electrodermal activity, heart rate, pupillography; in Steinhauer SR, Gruzelier JH, Zubin J (eds): Handbook of Schizophrenia, vol 5: Neuropsychology, Psychophysiology and Information Processing. Amsterdam, Elsevier, 1991, pp 185-224.